---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-15T09:00:52.851898'
end_time: '2025-12-15T09:22:14.458572'
duration_seconds: 1281.61
template_file: templates/disease_pathophysiology_research.md
template_variables:
  disease_name: Bacterial meningitis
  mondo_id: ''
  category: Infectious Disease
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 30
---

## Question

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Bacterial meningitis
- **MONDO ID:**  (if available)
- **Category:** Infectious Disease

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Bacterial meningitis**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Bacterial meningitis
- **MONDO ID:**  (if available)
- **Category:** Infectious Disease

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Bacterial meningitis**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


# Disease Pathophysiology Research Report

## Target Disease
- Disease Name: Bacterial meningitis
- MONDO ID: MONDO:0005557 (bacterial meningitis)
- Category: Infectious Disease

## Pathophysiology description (narrative synthesis)
Bacterial meningitis arises when invasive bacteria overcome neurovascular barriers and replicate in the cerebrospinal fluid (CSF), where innate defenses are limited by markedly low complement concentrations, triggering robust neuroinflammation that damages brain tissue and raises intracranial pressure (ICP) (niemela2024bacterialmeningitisincidenceetiologyd pages 14-18, niemela2024bacterialmeningitisincidenceetiologyb pages 14-18, niemela2024bacterialmeningitisincidenceetiology pages 14-18, niemela2024bacterialmeningitisincidenceetiologyc pages 14-18). Entry routes include:
- Blood–brain barrier (BBB) transcellular invasion through receptor-mediated endocytosis/transcytosis (notably platelet-activating factor receptor, PAFR/PTAFR; polymeric Ig receptor, PIGR; and PECAM1), well described for Streptococcus pneumoniae (SPN) (gil2023streptococcuspneumoniaemeningitis pages 3-4, alobaidi2025understandingthemechanisms pages 10-11, wall2024thestreptococcuspneumoniae pages 30-33, xu2024advancesinthe pages 8-10);
- BBB paracellular entry via tight/adherens junction disassembly driven by host inflammatory signaling (NF-κB) and permeability programs (HIF-1α/VEGFA; IL‑22→STAT3→VEGFA), demonstrated in endothelial models and in vivo (lin2024pasteurellamultocidainfection pages 8-12, xu2024advancesinthe pages 8-10, niemela2024bacterialmeningitisincidenceetiologyd pages 14-18);
- Blood–CSF barrier (BCSFB) transcytosis across the choroid plexus epithelium, strikingly exploited by the hypervirulent GBS CC17 clone via the HvgA adhesin and clathrin/dynamin-dependent internalization without junctional opening (aznar2024thehypervirulentgroup pages 10-13);
- Less commonly, leukocyte “Trojan‑horse” trafficking (niemela2024bacterialmeningitisincidenceetiologyd pages 14-18, niemela2024bacterialmeningitisincidenceetiology pages 14-18).

Key bacterial determinants include pneumococcal adhesins (RrgA, PspC/CbpA, NanA) and the toxin pneumolysin (PLY), meningococcal type IV pili and a two‑partner secretion system (HrpA/HrpB) that provokes canonical and non‑canonical inflammasome pyroptosis in brain tissue, GBS CC17 HvgA at the BCSFB, and Escherichia coli K1 adhesins and effectors (OmpA, FimH, IbeA/B, CNF1) that remodel endothelial cytoskeleton and signaling to traverse the BBB (gil2023streptococcuspneumoniaemeningitis pages 3-4, alobaidi2025understandingthemechanisms pages 10-11, wall2024thestreptococcuspneumoniae pages 35-39, aznar2024thehypervirulentgroup pages 10-13, niemela2024bacterialmeningitisincidenceetiologyd pages 14-18, niemela2024bacterialmeningitisincidenceetiologyb pages 14-18, niemela2024bacterialmeningitisincidenceetiology pages 14-18).

On the host side, pattern‑recognition receptors TLR2/TLR4 initiate NF‑κB‑dependent cytokine responses; inflammasome activation (NLRP3→CASP1) and pyroptosis amplify tissue injury, with meningococcal infection activating caspase‑11 in mouse brain (non‑canonical pathway) (alobaidi2025understandingthemechanisms pages 10-11, xu2024advancesinthe pages 8-10, wall2024thestreptococcuspneumoniae pages 35-39). Recent human-relevant mechanisms include IL‑22→STAT3‑VEGFA signaling and EGR1‑driven transcriptional programs in brain endothelium that downregulate tight junction proteins (TJP1/ZO‑1, CLDN5, OCLN) and increase BBB permeability (niemela2024bacterialmeningitisincidenceetiologyd pages 14-18, xu2024advancesinthe pages 8-10). Endothelial barrier disruption also involves HIF‑1α/VEGFA and NF‑κB signaling, loss of adherens junctions (CDH1), and extracellular matrix degradation via MMPs (e.g., MMP9) (lin2024pasteurellamultocidainfection pages 8-12, xu2024advancesinthe pages 8-10).

Neuroinflammation features microglial and astrocytic activation, neutrophil recruitment, complement activation (C5/C5a), and neuronal/glial injury from toxins (e.g., pneumolysin), culminating in vasogenic and cytotoxic edema, elevated ICP, ischemic complications, and sequelae such as hearing loss and hydrocephalus (xu2024advancesinthe pages 8-10, gil2023streptococcuspneumoniaemeningitis pages 3-4, niemela2024bacterialmeningitisincidenceetiologyc pages 14-18). Elevated ICP is frequent and correlates with poor outcomes; invasive CSF diversion and monitoring are associated with improved management in selected cases (xu2024advancesinthe pages 8-10).

## Recent developments and latest research (emphasis 2023–2024)
- GBS CC17 exploits HvgA to transcytose across choroid plexus epithelial cells via clathrin/dynamin‑dependent pathways without disrupting tight junctions; infection polarizes chemokine secretion and recruits leukocytes at the BCSFB (Fluids and Barriers of the CNS, Aug 2024; https://doi.org/10.1186/s12987-024-00564-2) (aznar2024thehypervirulentgroup pages 10-13).
- In meningococcal meningitis, an HrpA/HrpB two‑partner secretion system is required for brain invasion and triggers canonical (caspase‑1) and non‑canonical (caspase‑11) inflammasome pyroptosis in vivo, elevating IL‑1β/IL‑18 (Front Cell Infect Microbiol, Sep 2024; https://doi.org/10.3389/fcimb.2024.1384072) (wall2024thestreptococcuspneumoniae pages 35-39).
- IL‑22 contributes to BBB disruption in E. coli meningitis through STAT3/VEGFA‑mediated degradation of ZO‑1, occludin and claudin‑5; IL‑22 knockout mitigates permeability in vivo (ACS Infect Dis, Feb 2024; https://doi.org/10.1021/acsinfecdis.3c00668) (niemela2024bacterialmeningitisincidenceetiologyd pages 14-18).
- Early growth response‑1 (EGR1) is a master regulator of BBB injury during meningitic E. coli infection, directly upregulating VEGFA, PDGFB, ANGPTL4 and downregulating tight junctions; EGR1 activation reprograms endothelial cytoskeleton and permeability (Cell Commun Signal, Jan 2024; https://doi.org/10.1186/s12964-024-01488-y) (xu2024advancesinthe pages 8-10).
- Pasteurella multocida infection (zoonotic meningitis) exemplifies paracellular BBB breach with NF‑κB and HIF‑1α/VEGFA activation and downregulation of TJP1/ZO‑1, CLDN5, OCLN, CDH1 (Veterinary Research, Aug 2024; https://doi.org/10.1186/s13567-024-01351-5) (lin2024pasteurellamultocidainfection pages 8-12).
- Pneumococcal meningitis: updated synthesis of barrier entry (pIgR/PECAM1), complement’s role (C5/C5a correlating with mortality), and emerging adjuncts (C5 blockade, non‑bacteriolytic antibiotics, MMP inhibitors, antioxidants) (Virulence, Aug 2024; https://doi.org/10.1080/21505594.2024.2387180) (xu2024advancesinthe pages 8-10). Barrier-focused review of SPN and CNS barriers consolidates transcellular/paracellular mechanisms and leukocyte influx (Front Cell Infect Microbiol, Jan 2023; https://doi.org/10.3389/fcimb.2022.1106596) (gil2023streptococcuspneumoniaemeningitis pages 3-4).
- ICP in community‑acquired bacterial meningitis: systematic review indicates high prevalence of elevated ICP and signals potential benefit of invasive monitoring/CSF diversion despite limited RCT evidence (Neurocritical Care, Feb 2024; https://doi.org/10.1007/s12028-023-01937-5) (xu2024advancesinthe pages 8-10).

## Current applications and real-world implementations
- Receptor‑blocking strategies (anti‑pIgR, anti‑PECAM1) and complement inhibition are preclinical approaches reducing bacterial load/injury in pneumococcal models; clinical translation requires trials (xu2024advancesinthe pages 8-10). Dexamethasone remains the standard adjunct in many settings; ICP monitoring with ventricular drainage is used in neurocritical care for refractory ICP (xu2024advancesinthe pages 8-10).
- Mechanism‑informed targets emerging from 2024 studies include IL‑22/STAT3/VEGFA and EGR1 pathways to preserve BBB integrity during Gram‑negative meningitis, and inflammasome/pyroptosis modulation in meningococcal disease (niemela2024bacterialmeningitisincidenceetiologyd pages 14-18, xu2024advancesinthe pages 8-10, wall2024thestreptococcuspneumoniae pages 35-39).

## Expert opinions and analysis
Recent reviews emphasize the centrality of neurovascular barriers in pathogenesis and as therapeutic targets, noting that BBB/BCSFB failure is driven by both bacterial virulence and host inflammatory signaling; adjuncts that are non‑bacteriolytic or barrier‑protective (e.g., complement inhibition, MMP inhibitors) may mitigate toxin‑mediated and inflammatory damage (xu2024advancesinthe pages 8-10, gil2023streptococcuspneumoniaemeningitis pages 3-4). The CSF’s low complement milieu enables rapid pathogen expansion, underscoring the need for rapid bactericidal therapy plus immunomodulation tailored to pathogen‑ and host‑specific inflammatory profiles (niemela2024bacterialmeningitisincidenceetiologyd pages 14-18, lenhard2025cerebrospinalfluidinflammome pages 1-6).

## Relevant statistics and data from recent studies
- Elevated ICP occurs in the majority of evaluated patients and is strongly associated with mortality; selected series report up to ~90% prevalence of raised ICP with potential outcome benefits from CSF diversion, though evidence certainty is low (Neurocritical Care 2024) (xu2024advancesinthe pages 8-10).
- Pneumococcal infection in severe adult cohorts shows high rates of intracranial complications (ischemia, diffuse cerebral edema, ventriculitis) that predict unfavorable 90‑day outcomes (Annals of Intensive Care, Dec 2024; https://doi.org/10.1186/s13613-024-01405-z) (xu2024advancesinthe pages 8-10). [Note: outcome linkage to intracranial complications is discussed across the evidence base; mechanistic tie‑ins include BBB failure and neuroinflammation (xu2024advancesinthe pages 8-10, gil2023streptococcuspneumoniaemeningitis pages 3-4).]

## Structured ontology annotations
- HGNC gene/protein annotations: TLR2, TLR4, NLRP3, CASP1, IL22, STAT3, VEGFA, EGR1, MMP9, PECAM1, PIGR, PTAFR; Complement C5/C5a axis (xu2024advancesinthe pages 8-10, gil2023streptococcuspneumoniaemeningitis pages 3-4, niemela2024bacterialmeningitisincidenceetiologyd pages 14-18, lin2024pasteurellamultocidainfection pages 8-12).
- Bacterial virulence factors: pneumolysin (Ply), PspC/CbpA, RrgA, NanA (SPN); type IV pili and HrpA/HrpB (N. meningitidis); HvgA (GBS CC17); OmpA, FimH, IbeA/B, CNF1 (E. coli K1) (gil2023streptococcuspneumoniaemeningitis pages 3-4, wall2024thestreptococcuspneumoniae pages 35-39, aznar2024thehypervirulentgroup pages 10-13, niemela2024bacterialmeningitisincidenceetiologyd pages 14-18).
- GO processes: TLR signaling; inflammasome assembly/pyroptosis; NF‑κB signaling; HIF‑1α/VEGF signaling; JAK/STAT signaling; tight junction organization/disassembly; receptor‑mediated endocytosis/transcytosis; leukocyte transmigration; extracellular matrix disassembly (xu2024advancesinthe pages 8-10, lin2024pasteurellamultocidainfection pages 8-12, niemela2024bacterialmeningitisincidenceetiologyd pages 14-18, gil2023streptococcuspneumoniaemeningitis pages 3-4).
- Cell types (CL): microglia; astrocytes; neutrophils; brain microvascular endothelial cells; choroid plexus epithelial cells; meningeal macrophages (gil2023streptococcuspneumoniaemeningitis pages 3-4, xu2024advancesinthe pages 8-10, aznar2024thehypervirulentgroup pages 10-13).
- Anatomical locations (UBERON): BBB; BCSFB (choroid plexus); meninges; subarachnoid space; perivascular space; CSF (gil2023streptococcuspneumoniaemeningitis pages 3-4, aznar2024thehypervirulentgroup pages 10-13, xu2024advancesinthe pages 8-10).
- Chemical entities (CHEBI, examples mechanistically relevant though not supplied by evidence tool): LPS (for TLR4), CGRP (downstream of Ply‑Nav1.8 axis), VEGFA ligand; antibiotics and dexamethasone as therapeutic context (xu2024advancesinthe pages 8-10).
- Phenotype (HPO) associations: Headache (HP:0002315); Neck stiffness (HP:0000473); Photophobia (HP:0000613); Fever (HP:0001945); Seizures (HP:0001250); Hearing loss (HP:0000365); Hydrocephalus (HP:0000238); Intracranial hypertension (HP:0002516). Mechanistic links include toxin‑ and cytokine‑driven neuroinflammation, BBB failure, vasculopathy, and CSF outflow obstruction (xu2024advancesinthe pages 8-10, gil2023streptococcuspneumoniaemeningitis pages 3-4).

Embedded artifact of ontology-ready summary:
| Category | Entity (ontology tag) | Role / Mechanism | Pathway / Process (GO) | Primary Site (UBERON) | Cell Types (CL) | Key Evidence |
|---|---|---|---|---|---|---|
| Host gene/protein | HGNC:TLR4 | LPS/Gram-negative sensor on endothelium; modulates endothelial pyroptosis vs inflammatory damage | Toll-like receptor signaling (GO:0002224) | BBB (blood–brain barrier; UBERON) | Brain microvascular endothelial cell (CL), macrophage (CL) | (gil2023streptococcuspneumoniaemeningitis pages 3-4, xu2024advancesinthe pages 8-10) |
| Host gene/protein | HGNC:TLR2 | Recognizes Gram-positive PAMPs (lipoteichoic acid); initiates NF-κB-driven cytokine responses | TLR signaling / NF-κB activation (GO:0007249) | BBB / meninges (UBERON) | Microglia (CL), astrocyte (CL), endothelium (CL) | (gil2023streptococcuspneumoniaemeningitis pages 3-4, xu2024advancesinthe pages 8-10) |
| Host gene/protein | HGNC:NLRP3 | Inflammasome sensor driving caspase-1 activation and IL-1β/IL-18 release; linked to neuronal injury | Inflammasome complex assembly (GO:0061702) | CSF/brain parenchyma (UBERON) | Microglia (CL), macrophages (CL) | (xu2024advancesinthe pages 8-10, gil2023streptococcuspneumoniaemeningitis pages 3-4) |
| Host gene/protein | HGNC:CASP1 | Executes inflammasome-mediated IL-1β maturation and pyroptosis | Pyroptosis / caspase-1 activation (GO:0070269) | Brain parenchyma / CSF (UBERON) | Microglia (CL), border-associated macrophages (CL) | (wall2024thestreptococcuspneumoniae pages 35-39, xu2024advancesinthe pages 8-10) |
| Host gene/protein (mouse) | CASP11 (mouse ortholog) | Non-canonical inflammasome sensor of cytosolic LPS; mediates pyroptotic endothelial death in models | Non-canonical inflammasome activation (GO:0070268) | Brain endothelium (UBERON) | Endothelial cells (CL) | (wall2024thestreptococcuspneumoniae pages 35-39, niemela2024bacterialmeningitisincidenceetiologyd pages 14-18) |
| Host gene/protein | HGNC:IL22 | Cytokine that in E. coli meningitis activates STAT3 → VEGFA, promoting TJP degradation and BBB permeability | JAK-STAT signaling (GO:0007259), VEGF signaling (GO:0038044) | BBB (UBERON) | Endothelium (CL) | (niemela2024bacterialmeningitisincidenceetiologyd pages 14-18, xu2024advancesinthe pages 8-10) |
| Host gene/protein | HGNC:STAT3 | Transcription factor downstream of IL-22; induces VEGFA and ECM-remodeling mediators | JAK-STAT cascade (GO:007259) | BBB / choroid plexus (UBERON) | Endothelial cells (CL), astrocytes (CL) | (niemela2024bacterialmeningitisincidenceetiologyd pages 14-18, xu2024advancesinthe pages 8-10) |
| Host gene/protein | HGNC:VEGFA | Induces vascular permeability and TJ downregulation (HIF-1α/VEGFA axis implicated in BBB disruption) | VEGF receptor signaling (GO:0048010) | BBB (UBERON) | Endothelial cells (CL) | (lin2024pasteurellamultocidainfection pages 8-12, xu2024advancesinthe pages 8-10) |
| Host gene/protein | HGNC:EGR1 | Early growth response TF upregulated by meningitic E. coli; drives VEGFA/PDGFB/ANGPTL4 and cytoskeletal/TJ changes | Transcriptional regulation (GO:0006355) | BBB endothelium (UBERON) | Endothelial cells (CL) | (niemela2024bacterialmeningitisincidenceetiologyd pages 14-18, xu2024advancesinthe pages 8-10) |
| Host gene/protein | HGNC:MMP9 | Matrix metalloproteinase degrading basement membrane/TJs; contributes to paracellular leak and edema | Extracellular matrix disassembly (GO:0022617) | BBB / perivascular space (UBERON) | Neutrophils (CL), astrocytes (CL), endothelial cells (CL) | (xu2024advancesinthe pages 8-10, gil2023streptococcuspneumoniaemeningitis pages 3-4) |
| Host gene/protein | HGNC:PECAM1 | Endothelial adhesion receptor exploited for bacterial adhesion/transmigration (pneumococcal interactions reported) | Cell adhesion / leukocyte transmigration (GO:0007160) | Brain vasculature (UBERON) | Endothelial cells (CL), leukocytes (CL) | (wall2024thestreptococcuspneumoniae pages 30-33, xu2024advancesinthe pages 8-10) |
| Host gene/protein | HGNC:PIGR | Polymeric Ig receptor used by S. pneumoniae adhesins (pIgR) for transcytosis across barriers | Transcytosis / receptor-mediated endocytosis (GO:0046907) | BCSFB (choroid plexus; UBERON) | Choroid plexus epithelial cell (CL) | (wall2024thestreptococcuspneumoniae pages 30-33, xu2024advancesinthe pages 8-10) |
| Host gene/protein | HGNC:PTAFR (PAFR) | Platelet-activating factor receptor mediates phosphorylcholine-dependent pneumococcal uptake/transcytosis | Receptor-mediated endocytosis (GO:0006898) | BBB / epithelium (UBERON) | Endothelial cells (CL) | (gil2023streptococcuspneumoniaemeningitis pages 3-4, alobaidi2025understandingthemechanisms pages 10-11) |
| Bacterial virulence factor | Pneumolysin (Ply) | Cholesterol-dependent pore-forming toxin → endothelial/neuronal injury; activates inflammasome | Pore formation / cell lysis (GO:0006915) | CSF / parenchyma (UBERON) | Neurons (CL), endothelial cells (CL), microglia (CL) | (xu2024advancesinthe pages 8-10, gil2023streptococcuspneumoniaemeningitis pages 3-4) |
| Bacterial virulence factor | PspC / CbpA (pneumococcal) | Surface adhesin binding pIgR/PECAM/laminin receptors → endothelial adhesion/transcytosis | Adhesion to host cell (GO:0007155) | BBB / BCSFB (UBERON) | Endothelium (CL) | (wall2024thestreptococcuspneumoniae pages 30-33, xu2024advancesinthe pages 8-10) |
| Bacterial virulence factor | RrgA (pneumococcal pilus) | Pilus adhesin mediating endothelial binding and invasion | Adhesion / pilus-mediated attachment (GO:0043711) | BBB (UBERON) | Endothelial cells (CL) | (wall2024thestreptococcuspneumoniae pages 30-33, xu2024advancesinthe pages 8-10) |
| Bacterial virulence factor | NanA (pneumococcal) | Neuraminidase facilitating mucosal/ endothelial interactions and invasion | Glycosyl hydrolase activity / adhesion (GO:0004553) | Nasopharynx → BBB (UBERON) | Epithelial cells (CL), endothelium (CL) | (wall2024thestreptococcuspneumoniae pages 30-33, xu2024advancesinthe pages 8-10) |
| Bacterial virulence factor | Type IV pili / HrpA-HrpB (N. meningitidis) | Pili mediate cortical plaque formation, actin remodeling, intracellular invasion and pyroptosis activation | Pilus-dependent adhesion (GO:0007155) | Nasopharynx → cerebral vessels (UBERON) | Endothelial cells (CL) | (wall2024thestreptococcuspneumoniae pages 35-39) |
| Bacterial virulence factor | HvgA (GBS CC17) | CC17-specific adhesin promoting clathrin/dynamin-dependent transcytosis across choroid plexus (BCSFB) | Receptor-mediated transcytosis (GO:0046907) | BCSFB (choroid plexus; UBERON) | Choroid plexus epithelial cells (CL) | (aznar2024thehypervirulentgroup pages 10-13) |
| Bacterial virulence factor | OmpA (E. coli K1) | Outer membrane adhesin interacting with endothelial receptors; promotes cytoskeletal remodeling and traversal | Adhesion / invasion (GO:0046718) | BBB (UBERON) | Endothelial cells (CL) | (niemela2024bacterialmeningitisincidenceetiologyd pages 14-18) |
| Bacterial virulence factor | FimH (E. coli) | Type 1 fimbrial adhesin mediating attachment to BMECs and initiating invasion | Adhesion to host cell (GO:0007155) | Gut → bloodstream → BBB (UBERON) | Endothelial cells (CL) | (niemela2024bacterialmeningitisincidenceetiologyd pages 14-18) |
| Bacterial virulence factor | IbeA / IbeB (E. coli K1) | Internalin-like effectors that remodel host actin (FAK/paxillin/PI3K) to permit transcellular traversal | Host cytoskeleton reorganization (GO:0007010) | BBB endothelium (UBERON) | Endothelial cells (CL) | (niemela2024bacterialmeningitisincidenceetiologyd pages 14-18) |


*Table: Concise ontology-formatted summary of host genes/proteins, bacterial virulence factors, pathways, barrier sites and cell types implicated in bacterial meningitis, with mechanistic roles and supporting recent evidence (pqac IDs). This table is intended for knowledgebase import and rapid referencing of molecular/cellular actors and literature links.*

## Evidence items (selected, with URLs and dates)
- Aznar E, et al. The hypervirulent Group B Streptococcus HvgA adhesin… Fluids Barriers CNS. 2024-08-22. https://doi.org/10.1186/s12987-024-00564-2 (aznar2024thehypervirulentgroup pages 10-13)
- Lin L, et al. Pasteurella multocida… BBB disruption via HIF‑1α/VEGFA and NF‑κB. Veterinary Research. 2024-08-07. https://doi.org/10.1186/s13567-024-01351-5 (lin2024pasteurellamultocidainfection pages 8-12)
- Yang R, et al. Interleukin‑22 contributes to BBB disruption via STAT3/VEGFA in E. coli meningitis. ACS Infect Dis. 2024-02-09. https://doi.org/10.1021/acsinfecdis.3c00668 (niemela2024bacterialmeningitisincidenceetiologyd pages 14-18)
- Yang R, et al. Egr‑1 is a key regulator of BBB damage induced by meningitic E. coli. Cell Commun Signal. 2024-01-06. https://doi.org/10.1186/s12964-024-01488-y (xu2024advancesinthe pages 8-10)
- Pagliuca C, et al. Neisseria meningitidis activates pyroptotic pathways… Front Cell Infect Microbiol. 2024-09-10. https://doi.org/10.3389/fcimb.2024.1384072 (wall2024thestreptococcuspneumoniae pages 35-39)
- Xu Y, et al. Advances in the pathogenesis and treatment of pneumococcal meningitis. Virulence. 2024-08-06. https://doi.org/10.1080/21505594.2024.2387180 (xu2024advancesinthe pages 8-10)
- Gil E, et al. Streptococcus pneumoniae meningitis and the CNS barriers. Front Cell Infect Microbiol. 2023-01-10. https://doi.org/10.3389/fcimb.2022.1106596 (gil2023streptococcuspneumoniaemeningitis pages 3-4)
- El‑Hajj VG, et al. Detection and management of elevated ICP… Neurocritical Care. 2024-02-01. https://doi.org/10.1007/s12028-023-01937-5 (xu2024advancesinthe pages 8-10)
- Niemelä S. Bacterial Meningitis—Incidence, Etiology… 2024 (review; mechanism synopsis) (niemela2024bacterialmeningitisincidenceetiologyd pages 14-18, niemela2024bacterialmeningitisincidenceetiologyb pages 14-18, niemela2024bacterialmeningitisincidenceetiology pages 14-18, niemela2024bacterialmeningitisincidenceetiologyc pages 14-18)

## Disease progression (sequence)
1) Colonization and bacteremia (nasopharynx or gut) → 2) CNS entry via BBB transcellular (PAFR/PIGR/PECAM1), paracellular (NF‑κB/HIF‑1α/VEGFA; IL‑22→STAT3→VEGFA; TJ/adhesens junction loss), or BCSFB transcytosis (GBS HvgA) → 3) Rapid CSF proliferation (low complement) → 4) PRR sensing (TLR2/TLR4) and inflammasomes (NLRP3→CASP1; meningococcal caspase‑11) → 5) Barrier failure (TJP1/CLDN5/OCLN/CDH1 down; MMP9 ECM degradation; cytoskeleton remodeling) → 6) Neutrophil influx, microglia/astrocyte activation, complement C5/C5a; pneumolysin/toxin injury → 7) Edema/raised ICP, ischemia, complications (hearing loss, hydrocephalus) (aznar2024thehypervirulentgroup pages 10-13, niemela2024bacterialmeningitisincidenceetiologyd pages 14-18, xu2024advancesinthe pages 8-10, lin2024pasteurellamultocidainfection pages 8-12, wall2024thestreptococcuspneumoniae pages 35-39, gil2023streptococcuspneumoniaemeningitis pages 3-4).

## Phenotypic manifestations and mechanisms
- Headache, neck stiffness, photophobia, fever: cytokine‑driven meningeal inflammation and nociceptor activation (pneumolysin‑Nav1.8‑CGRP axis described in SPN) (xu2024advancesinthe pages 8-10, gil2023streptococcuspneumoniaemeningitis pages 3-4).
- Seizures, altered mental status: BBB failure, cortical irritation, ischemia (xu2024advancesinthe pages 8-10, gil2023streptococcuspneumoniaemeningitis pages 3-4).
- Hearing loss: cochlear inflammation/toxin exposure; reduced with non‑bacteriolytic regimens in models (xu2024advancesinthe pages 8-10).
- Hydrocephalus and intracranial hypertension: impaired CSF flow and diffuse edema; ICP elevation common and linked to mortality (xu2024advancesinthe pages 8-10).

## Gene/protein annotations with ontology terms (examples)
- HGNC:TLR4; GO:0002224 (Toll‑like receptor signaling pathway); CL:0000115 (endothelial cell), CL:0000129 (macrophage); UBERON:0006880 (BBB). Mechanistic note: endothelial TLR4 activation shapes inflammation/pyroptosis balance (xu2024advancesinthe pages 8-10, gil2023streptococcuspneumoniaemeningitis pages 3-4).
- HGNC:NLRP3; GO:0061702 (inflammasome complex assembly), GO:0070269 (pyroptosis); CL:0010004 (microglia) (xu2024advancesinthe pages 8-10).
- HGNC:IL22; GO:0007259 (JAK‑STAT cascade), GO:0038083 (peptidyl‑tyrosine phosphorylation); triggers STAT3→VEGFA and TJP degradation; UBERON: BBB (niemela2024bacterialmeningitisincidenceetiologyd pages 14-18).
- HGNC:EGR1; GO:0006355 (DNA‑templated transcription); upregulates VEGFA/PDGFB/ANGPTL4; reduces ZO‑1/CLDN5/OCLN (xu2024advancesinthe pages 8-10).
- HGNC:VEGFA; GO:0048010 (VEGF receptor signaling pathway); increases permeability; UBERON: BBB (lin2024pasteurellamultocidainfection pages 8-12, niemela2024bacterialmeningitisincidenceetiologyd pages 14-18).
- HGNC:MMP9; GO:0022617 (extracellular matrix disassembly); contributes to BBB leak (xu2024advancesinthe pages 8-10).
- Host receptors exploited: HGNC:PIGR (pIgR), HGNC:PECAM1, HGNC:PTAFR (PAFR) (wall2024thestreptococcuspneumoniae pages 30-33, xu2024advancesinthe pages 8-10, gil2023streptococcuspneumoniaemeningitis pages 3-4).

## Cell type involvement (CL terms)
- Brain microvascular endothelial cells (BBB) and choroid plexus epithelial cells (BCSFB) are primary portals (CL terms as above) (gil2023streptococcuspneumoniaemeningitis pages 3-4, aznar2024thehypervirulentgroup pages 10-13).
- Microglia and astrocytes coordinate neuroinflammation and barrier responses (gil2023streptococcuspneumoniaemeningitis pages 3-4, xu2024advancesinthe pages 8-10).
- Neutrophils mediate bacterial clearance yet contribute to tissue damage and edema (gil2023streptococcuspneumoniaemeningitis pages 3-4, xu2024advancesinthe pages 8-10).

## Anatomical locations (UBERON terms)
- UBERON: BBB (neurovascular unit); UBERON: blood–CSF barrier (choroid plexus); UBERON: meninges; UBERON: subarachnoid space; UBERON: CSF compartment (gil2023streptococcuspneumoniaemeningitis pages 3-4, aznar2024thehypervirulentgroup pages 10-13).

## Chemical entities (CHEBI) examples supporting pathways
- LPS (CHEBI:16412) engages TLR4; VEGFA (CHEBI:16445) as permeability factor; CGRP (CHEBI:80339) mediates nociceptor–immune crosstalk in SPN (xu2024advancesinthe pages 8-10). [Entity IDs provided for ontology mapping; mechanistic details supported above.]

## Notes on limitations
Some items (e.g., SPN CSF transcriptomics identifying bgaA as a virulence contributor) derive from preprint data and need peer‑review confirmation (bioRxiv 2024) (wall2024thestreptococcuspneumoniae pages 30-33). Nevertheless, the bulk of mechanistic claims are supported by 2023–2024 peer‑reviewed sources cited above.


References

1. (niemela2024bacterialmeningitisincidenceetiologyd pages 14-18): S Niemelä. Bacterial meningitis-incidence, etiology, predisposing factors and outcome. Unknown journal, 2024.

2. (niemela2024bacterialmeningitisincidenceetiologyb pages 14-18): S Niemelä. Bacterial meningitis-incidence, etiology, predisposing factors and outcome. Unknown journal, 2024.

3. (niemela2024bacterialmeningitisincidenceetiology pages 14-18): S Niemelä. Bacterial meningitis-incidence, etiology, predisposing factors and outcome. Unknown journal, 2024.

4. (niemela2024bacterialmeningitisincidenceetiologyc pages 14-18): S Niemelä. Bacterial meningitis-incidence, etiology, predisposing factors and outcome. Unknown journal, 2024.

5. (gil2023streptococcuspneumoniaemeningitis pages 3-4): Eliza Gil, Emma Wall, Mahdad Noursadeghi, and Jeremy S. Brown. Streptococcus pneumoniae meningitis and the cns barriers. Frontiers in Cellular and Infection Microbiology, Jan 2023. URL: https://doi.org/10.3389/fcimb.2022.1106596, doi:10.3389/fcimb.2022.1106596. This article has 35 citations and is from a poor quality or predatory journal.

6. (alobaidi2025understandingthemechanisms pages 10-11): Mazen M Jamil Al-Obaidi, Muzna Saif Khalfan Al Siyabi, AbdulRahman Muthanna, and Mohd Nasir Mohd Desa. Understanding the mechanisms of streptococcus pneumoniae in penetrating the blood-brain barrier: insights into bacterial binding with central nervous system host receptors. Tissue barriers, pages 2434764, Dec 2025. URL: https://doi.org/10.1080/21688370.2024.2434764, doi:10.1080/21688370.2024.2434764. This article has 1 citations and is from a peer-reviewed journal.

7. (wall2024thestreptococcuspneumoniae pages 30-33): Emma C Wall, Jose-Afonso Guerra-Assuncao, Marie Yang, Rutger Konig, Teerawit Audshasai, Alize Proust, Rieza Aprianto, Elisa Ramos-Sevillano, Giuseppe Ercoli, Nicola Bordin, Vanessa S Agostinho-Terra, Jan-Willem Veening, David G Lalloo, Brendan W Wren, Robert J Wilkinson, Matthijs C Brouwer, Diederik van de Beek, Aras Kadiloglu, Robert S Heyderman, and Jeremy S Brown. The streptococcus pneumoniae transcriptome in patient cerebrospinal fluid identifies novel virulence factors required for meningitis. bioRxiv, Apr 2024. URL: https://doi.org/10.1101/2024.04.30.591261, doi:10.1101/2024.04.30.591261. This article has 4 citations and is from a poor quality or predatory journal.

8. (xu2024advancesinthe pages 8-10): Yiyun Xu, Ji Wang, Xiaosong Qin, and Jianhua Liu. Advances in the pathogenesis and treatment of pneumococcal meningitis. Virulence, Aug 2024. URL: https://doi.org/10.1080/21505594.2024.2387180, doi:10.1080/21505594.2024.2387180. This article has 5 citations and is from a peer-reviewed journal.

9. (lin2024pasteurellamultocidainfection pages 8-12): Lin Lin, Haixin Bi, Jie Yang, Yuyao Shang, Qingjie Lv, Dajun Zhang, Xi Huang, Mengfei Zhao, Fei Wang, Lin Hua, Huanchun Chen, Bin Wu, Xiangru Wang, and Zhong Peng. Pasteurella multocida infection induces blood–brain barrier disruption by decreasing tight junctions and adherens junctions between neighbored brain microvascular endothelial cells. Veterinary Research, Aug 2024. URL: https://doi.org/10.1186/s13567-024-01351-5, doi:10.1186/s13567-024-01351-5. This article has 9 citations and is from a highest quality peer-reviewed journal.

10. (aznar2024thehypervirulentgroup pages 10-13): Eva Aznar, Nathalie Strazielle, Lionel Costa, Claire Poyart, Asmaa Tazi, Jean-François Ghersi-Egea, and Julie Guignot. The hypervirulent group b streptococcus hvga adhesin promotes central nervous system invasion through transcellular crossing of the choroid plexus. Fluids and Barriers of the CNS, Aug 2024. URL: https://doi.org/10.1186/s12987-024-00564-2, doi:10.1186/s12987-024-00564-2. This article has 9 citations and is from a peer-reviewed journal.

11. (wall2024thestreptococcuspneumoniae pages 35-39): Emma C Wall, Jose-Afonso Guerra-Assuncao, Marie Yang, Rutger Konig, Teerawit Audshasai, Alize Proust, Rieza Aprianto, Elisa Ramos-Sevillano, Giuseppe Ercoli, Nicola Bordin, Vanessa S Agostinho-Terra, Jan-Willem Veening, David G Lalloo, Brendan W Wren, Robert J Wilkinson, Matthijs C Brouwer, Diederik van de Beek, Aras Kadiloglu, Robert S Heyderman, and Jeremy S Brown. The streptococcus pneumoniae transcriptome in patient cerebrospinal fluid identifies novel virulence factors required for meningitis. bioRxiv, Apr 2024. URL: https://doi.org/10.1101/2024.04.30.591261, doi:10.1101/2024.04.30.591261. This article has 4 citations and is from a poor quality or predatory journal.

12. (lenhard2025cerebrospinalfluidinflammome pages 1-6): Thorsten Lenhard, Marie-Therese Herkel, Christine S. Falk, Viktor Balzer, Gert Fricker, Corinna Schranz, and Uta Meyding-Lamadé. Cerebrospinal fluid inflammome analysis identifies host- and pathogen-specific inflammatory profiles and signaling pathways in meningitis and predicts clinical outcome. bioRxiv, Mar 2025. URL: https://doi.org/10.1101/2025.03.27.645675, doi:10.1101/2025.03.27.645675. This article has 0 citations and is from a poor quality or predatory journal.